



PB 57 of 2020

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under paragraph 98C(1) of the *National Health Act 1953*.

Dated 29th June 2020

THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health

1 Name of Instrument

- (1) This Instrument is the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2020 (No. 4)*.
- (2) This Instrument may also be cited as PB 57 of 2020.

2 Commencement

This Instrument commences on 1 July 2020.

3 Amendments to *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019*

Schedule 1 amends the *National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019*.

Schedule 1 Amendments

[1] Part 1, Section 6 (definition of extemporaneously-prepared pharmaceutical benefit)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[2] Part 2, Subsection 7(2)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[3] Part 2, Section 7 (Note)

omit: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2015 (PB 64 of 2015)

substitute: Commonwealth price (Pharmaceutical benefits supplied by approved pharmacists) Determination 2020 (PB 66 of 2020)

[4] Schedule 4, after entry for Budesonide with formoterol in the form Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses, 2

insert:

Budesonide with formoterol	Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses
----------------------------	---

[5] Schedule 4, omit entry for Mepolizumab

[6] Schedule 4, after entry for Salmeterol

insert:

Semaglutide	Solution for injection 2 mg in 1.5 mL pre-filled pen
Semaglutide	Solution for injection 4 mg in 3 mL pre-filled pen
